Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in children
- 1Astellas Pharma Global, Inc., Northbrook, Illinois, USA
- 2Astellas Pharma, Inc., Tokyo, Japan
- 3Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, RadboudUMC-CWZ Center of Expertise in Mycology, Nijmegen, the Netherlands
Abstract
Invasive fungal diseases (IFDs), including invasive aspergillosis (IA) and invasive mucormycosis (IM), occur primarily in immunocompromised and/or hospitalized patients and are associated with increased morbidity and mortality. Isavuconazole and posaconazole are triazole compounds approved for the treatment of IA/IM in adults and children, while voriconazole is approved for IA treatment only. All triazole compounds inhibit CYP3A, and both isavuconazole and posaconazole inhibit the transporter P-gp. Pediatric patients being treated for leukemia with vincristine frequently experience fungal infections, requiring treatment. Vincristine is metabolized by CYP3A4 and CYP3A5 and eliminated via P-gp transport. The risk of drug-drug interactions (DDIs) between vincristine and triazole compounds is known; however, the magnitude of risk has not been quantified. In the present analysis, physiologically based pharmacokinetic (PBPK) models were built for the triazoles and vincristine in a pediatric cancer population using the Simcyp simulator and were used to predict the change in vincristine exposure following coadministration with triazoles. Different age groups and CYP3A5 phenotypes were also explored. Modeling predicted that vincristine geometric mean AUCinf ratios in CYP3A5 poor metabolizers (PMs) ranged from 2.01- to 2.25-fold, 4.97- to 5.20-fold, and 1.43- to 1.53-fold with isavuconazole, posaconazole, and voriconazole, respectively. In CYP3A5 extensive metabolizers (EMs), vincristine AUCinf ratios ranged from 1.22- to 1.38-fold, 1.19- to 1.24-fold, and 1.05- to 1.07-fold for isavuconazole, posaconazole, and voriconazole, respectively. The model predicted vincristine AUCinf >100 ng·h/mL in CYP3A5 PM and <100 ng·h/mL in CYP3A5 EM; therefore, vincristine dose reduction may be required only in CYP3A5 null expressors.
Related
- Physiologically Based Pharmacokinetic Modeling of Venetoclax in Pediatric Acute Myeloid Leukemia: Food Effects, Age-Related Pharmacokinetics, and Voriconazole-Mediated Drug-Drug Interactions.
- Population pharmacokinetic model library for isavuconazole: development and quality control
- Physiologically-based pharmacokinetic model to predict pharmacokinetics of KY0467 in humans and guide dose selection in infants and children
- Population pharmacokinetic modeling of voriconazole based on real-world data for dosing regimen optimization
- Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Aficamten in the Chinese Population.
BibTeX
@article{choules2026physiologically,
title = {{Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in children}},
author = {Mary P. Choules and Amit Desai and Laura Lynn Kovanda and Yukio Otsuka and Roger J. Brüggemann and Peter L. Bonate},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
month = jul,
doi = {10.1128/aac.00444-26},
url = {https://doi.org/10.1128/aac.00444-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in children
AU - Mary P. Choules
AU - Amit Desai
AU - Laura Lynn Kovanda
AU - Yukio Otsuka
AU - Roger J. Brüggemann
AU - Peter L. Bonate
PY - 2026
DA - 2026/07/22
JO - Antimicrobial Agents and Chemotherapy
DO - 10.1128/aac.00444-26
UR - https://doi.org/10.1128/aac.00444-26
AB - Invasive fungal diseases (IFDs), including invasive aspergillosis (IA) and invasive mucormycosis (IM), occur primarily in immunocompromised and/or hospitalized patients and are associated with increased morbidity and mortality. Isavuconazole and posaconazole are triazole compounds approved for the treatment of IA/IM in adults and children, while voriconazole is approved for IA treatment only. All triazole compounds inhibit CYP3A, and both isavuconazole and posaconazole inhibit the transporter P-gp. Pediatric patients being treated for leukemia with vincristine frequently experience fungal infections, requiring treatment. Vincristine is metabolized by CYP3A4 and CYP3A5 and eliminated via P-gp transport. The risk of drug-drug interactions (DDIs) between vincristine and triazole compounds is known; however, the magnitude of risk has not been quantified. In the present analysis, physiologically based pharmacokinetic (PBPK) models were built for the triazoles and vincristine in a pediatric cancer population using the Simcyp simulator and were used to predict the change in vincristine exposure following coadministration with triazoles. Different age groups and CYP3A5 phenotypes were also explored. Modeling predicted that vincristine geometric mean AUCinf ratios in CYP3A5 poor metabolizers (PMs) ranged from 2.01- to 2.25-fold, 4.97- to 5.20-fold, and 1.43- to 1.53-fold with isavuconazole, posaconazole, and voriconazole, respectively. In CYP3A5 extensive metabolizers (EMs), vincristine AUCinf ratios ranged from 1.22- to 1.38-fold, 1.19- to 1.24-fold, and 1.05- to 1.07-fold for isavuconazole, posaconazole, and voriconazole, respectively. The model predicted vincristine AUCinf >100 ng·h/mL in CYP3A5 PM and <100 ng·h/mL in CYP3A5 EM; therefore, vincristine dose reduction may be required only in CYP3A5 null expressors.
SN - 0066-4804
SN - 1098-6596
ER -